PGCM
BIB icon

Prescott Group Capital Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Prescott Group Capital Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,000
Closed -$210K – 104
2020
Q3 		$210K Hold
3,000
– – 0.09% 98
2020
Q2 		$218K Buy
+3,000
New +$192K 0.11% 87

Other funds holding BIB

SFS
Sowell Financial Services North Little Rock, Arkansas $2.7B AUM 22.62% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
UMC
United Maritime Capital New York $15.2M AUM 45.42% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Prescott Group Capital Management's BIB Position: Q4 2020 in Review

Prescott Group Capital Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2020, closing a stake of 3,000 shares — an estimated $210K sold.

Prescott Group Capital Management first reported a position in BIB in Q2 2020 and held it in 2 quarters. The position peaked at $218K in Q2 2020. 34 funds tracked by Wall St. Rank hold BIB as of Q4 2020.

  • Prescott Group Capital Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2020 after selling out during the quarter.
  • Prescott Group Capital Management sold 3,000 ProShares Ultra NASDAQ Biotechnology shares in Q4 2020, an estimated $210K.
  • Prescott Group Capital Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2020 and held it in 2 quarters.
  • Prescott Group Capital Management's ProShares Ultra NASDAQ Biotechnology position peaked at $218K in Q2 2020.
  • 34 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2020.

Based on Prescott Group Capital Management's 13F filing for Q4 2020, filed 10 Feb 2021.